Promedior Appoints Richard Jack, PhD, as Chief Scientific Officer
—Industry R&D Veteran to Support Advancing Pipeline of Novel Therapeutics for Fibrosis—
LEXINGTON, Mass., February 10, 2014 — Promedior, Inc.
, a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that biotechnology veteran and immunology expert Richard Jack, PhD, has joined the company as its Chief Scientific Officer. Dr. Jack will be responsible for directing Promedior’s research and development activities in support of the company’s drug candidates targeting fibrosis, including lead drug programs that are successfully advancing through clinical studies for serious and life threatening fibrotic diseases, including myelofibrosis and idiopathic pulmonary fibrosis (IPF).
We are pleased to welcome Rick to Promedior’s leadership team," said Suzanne L. Bruhn, PhD, President and Chief Executive Officer of Promedior. “His strong experience in leading-edge drug development, along with his deep knowledge of immunology, strengthens our team as we accelerate our clinical programs and continue to broaden our pipeline of disease-modifying anti-fibrotic therapeutic candidates.”
"I am excited to join Promedior to advance its novel Pentraxin-2-based platform to develop therapeutics to treat diseases involving fibrosis," said Richard Jack, PhD, Chief Scientific Officer for Promedior. "I see tremendous potential for Promedior's innovative therapeutics to harness the healing power of the innate immune system, opening up new opportunities to treat a wide range of systemic fibrotic diseases for which there are currently no approved therapies."
Richard Jack, PhD, has more than 15 years of drug discovery research and development experience in the biotechnology and pharmaceutical companies. Most recently, he led the research efforts at Madera Biosciences, a company developing small molecules for the clearance of amyloid β in neurodegenerative diseases. Prior to joining Madera, he was Vice President of Research for Tanabe Research Labs-USA (TRL), the US discovery arm of Mitsubishi-Tanabe Pharma. While there, he and his team advanced multiple small molecule programs to development. Prior to his tenure at TRL, Dr. Jack was a scientific cofounder and Vice President, Biology at Triad Therapeutics, a structure-based drug discovery company that developed a leading kinase inhibitor program that was licensed to Novartis and advanced into human clinical trials. He began his biopharmaceutical career at La Jolla Pharmaceutical, where he developed and advanced preclinical and clinical biologics programs for antibody-mediated diseases.
Prior to his work in the biopharmaceutical industry, Dr. Jack spent more than 10 years in the Department of Rheumatology/Immunology at Brigham and Women's Hospital/Harvard Medical School where he was also an NIH-funded faculty member of the graduate programs for both Immunology and Cell and Molecular Biology. His lab focused on mechanisms of autoimmune and inflammatory disease particularly in the areas of the complement system and leukocyte activation. Dr. Jack is an author of more than 50 scientific papers and three patents. He received an AB in Biology from Bates College, earned a PhD in Immunology from the University of Connecticut Health Center and performed his postdoctoral fellowship in Immunoparasitology at ILRAD in Nairobi, Kenya.
Promedior is a clinical stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is specifically active at the site of tissue damage and works as an agonist, preventing and potentially reversing fibrosis.
Promedior has successfully advanced its lead therapeutic candidate in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com
The Yates Network